<DOC>
	<DOCNO>NCT00682630</DOCNO>
	<brief_summary>The objective study determine bioequivalence combination pyronaridine artesunate ( 180:60mg ) to-be-marketed tablet clinical trial reference tablet administer single total dose 720:240 mg healthy adult .</brief_summary>
	<brief_title>Bioequivalence Pyronaridine Artesunate to-be-Marketed Tablet Clinical Trial Reference Tablet</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Pyronaridine</mesh_term>
	<criteria>1 . Male female subject age 18 45 year body weight 55 75 kg body mass index use Quetelet 's Index weight ( kg ) /height2 ( m2 ) 1828 2 . Signed date write informed consent form undergo study related activity , include discontinuation prohibit medication 3 . Medically normal subject significant abnormal finding screen physical examination evaluate clinical investigator 4 . Normal ( abnormal clinically insignificant ) laboratory value screen 1 . Known history evidence clinically significant disorder cardiovascular ( include arrhythmia , acute QTc interval great equal 450 mseconds ) , respiratory ( include active tuberculosis ) , hepatic , renal , gastrointestinal , immunological ( include active HIVAIDS ) , neurological ( include auditory ) , endocrine , infectious , malignancy , psychiatric abnormality ( include head trauma ) 2 . Known history hypersensitivity , allergic adverse reaction pyronaridine artesunate artemisinins</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Malaria</keyword>
	<keyword>anti-malarial</keyword>
	<keyword>pyronaridine</keyword>
	<keyword>ACT</keyword>
</DOC>